Potential utility of [Ga-68]DOTA-FAPI-04 as a broad-spectrum benign disease imaging agent-comparison with [F-18]FDG and [Tc-99m]MDP

作者全名："Li, Yi; Deng, Li; Feng, Yue; Liu, Lin; Lv, Furong; Qiu, Lin"

作者地址："[Li, Yi; Deng, Li; Lv, Furong] Chongqing Med Univ, Affiliated Hosp 1, 1 Youyi Rd, Chongqing 400000, Peoples R China; [Li, Yi; Feng, Yue; Liu, Lin; Qiu, Lin] Southwest Med Univ, Affiliated Hosp, Dept Nucl Med, 25 Taiping St, Luzhou 646000, Sichuan, Peoples R China; [Li, Yi; Deng, Li; Feng, Yue; Liu, Lin; Qiu, Lin] Nucl Med & Mol Imaging Key Lab Sichuan Prov, Luzhou 646000, Sichuan, Peoples R China; [Li, Yi; Deng, Li; Feng, Yue; Liu, Lin; Qiu, Lin] Southwest Med Univ, Nucl Med Inst, Luzhou 646000, Sichuan, Peoples R China; [Deng, Li] Southwest Med Univ, Affiliated Hosp, Dept Dermatol, 25 Taiping St, Luzhou 646000, Sichuan, Peoples R China"

通信作者："Lv, FR (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, 1 Youyi Rd, Chongqing 400000, Peoples R China.; Qiu, L (通讯作者)，Southwest Med Univ, Affiliated Hosp, Dept Nucl Med, 25 Taiping St, Luzhou 646000, Sichuan, Peoples R China.; Qiu, L (通讯作者)，Nucl Med & Mol Imaging Key Lab Sichuan Prov, Luzhou 646000, Sichuan, Peoples R China.; Qiu, L (通讯作者)，Southwest Med Univ, Nucl Med Inst, Luzhou 646000, Sichuan, Peoples R China."

来源：EUROPEAN RADIOLOGY

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:001029358200001

JCR分区：Q1

影响因子：4.7

年份：2023

卷号：　

期号：　

开始页：　

结束页：　

文献类型：Article; Early Access

关键词：68 Ga-FAPI; [F-18]FDG; Inflammation; Benign neoplasms

摘要："ObjectivesTo compare the detection performance of [Ga-68]DOTA-FAPI-04 positron emission tomography/computed tomography (PET/CT) and [F-18]FDG PET/CT for patients with various benign diseases and that of [Ga-68]DOTA-FAPI-04 PET/CT and [Tc-99m]MDP single-photon emission computed tomography/computed tomography (SPECT/CT) for patients with benign bone lesions.MethodsThis prospective study included 89 patients who underwent [F-18]FDG and [Ga-68]DOTA-FAPI-04 PET/CT and 22 patients who underwent [Tc-99m]MDP SPECT/CT and [Ga-68]DOTA-FAPI-04 PET/CT. Detection performance of [Ga-68]DOTA-FAPI-04, [F-18]FDG PET/CT, and [Tc-99m]MDP SPECT/CT for benign lesions was compared using the T/B value, T value, and true positive rate. Paired sample t-tests were conducted for comparisons.ResultsThis study comprised 53 men and 58 women (mean age, 53 & PLUSMN; 15.75 years). [Ga-68]DOTA-FAPI-04 demonstrated a higher uptake and detection rate for fibrotic disease (SUVmax [FAPI vs FDG: 6.26 & PLUSMN; 1.61 vs 2.38 & PLUSMN; 1.26], p1 < 0.001; T/B value [FAPI vs FDG: 9.38 & PLUSMN; 2.78 vs 1.95 & PLUSMN; 1.33], p2 < 0.001; and true positive rate 100% vs 26.3%), infectious disease (T/B value [FAPI vs FDG: 14.15 & PLUSMN; 12.42 vs 6.70 & PLUSMN; 5.87], p2 < 0.05; and true positive rate 94% vs 82%), and benign tumor (T/B value [FAPI vs FDG: 6.49 & PLUSMN; 5.85 vs 1.96 & PLUSMN; 2.03], p2 < 0.05; and true positive rate 70% vs 52%) than [F-18]FDG. [Ga-68]DOTA-FAPI-04 demonstrated a lower uptake and a comparable detection rate for benign bone disease (T/B value [FAPI vs FDG: 5.46 & PLUSMN; 2.91 vs 23.58 & PLUSMN; 15.37], p < 0.001; and true positive rate 90% vs 99%) than [Tc-99m]MDP.Conclusion[Ga-68]DOTA-FAPI-04 could be used as a benign disease imaging agent to complement traditional nuclide imaging agents."

基金机构：Luzhou Science amp; Technology Department [20107]; Affiliated Hospital of Southwest Medical University [20087]

基金资助正文：This study was supported in part by research foundation projects from Luzhou Science & amp; Technology Department (20107) and The Affiliated Hospital of Southwest Medical University (20087).